KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

被引：0
|
作者：
Schmid, P. [1 ]
Cortes, J. [2 ,3 ,4 ]
Dent, R. [5 ]
Pusztai, L. [6 ]
McArthur, H. L. [7 ]
Kuemmel, S. [8 ]
Bergh, J. [9 ,10 ]
Denkert, C. [11 ]
Park, Y. H. [12 ]
Hui, R. [13 ,14 ]
Harbeck, N. [15 ]
Takahashi, M. [16 ]
Foukakis, T. [9 ,10 ]
Fasching, P. A. [17 ]
Cardoso, F. [18 ]
Jia, L. [19 ]
Karantza, V. [20 ]
Zhao, J. [21 ]
Aktan, G. [20 ]
O'Shaughnessy, J. [22 ]
机构：
[1] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England
[2] IOB Inst Oncol, Quironsalud Grp, Oncol Dept, Madrid, Spain
[3] IOB Inst Oncol, Quironsalud Grp, Oncol Dept, Barcelona, Spain
[4] Vall dHebron Intitute Oncol VHIO, Barcelona, Spain
[5] Univ Toronto, Toronto, ON, Canada
[6] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA
[7] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA
[8] Kliniken Essen Mitte Evang, Breast Unit, Essen, Germany
[9] Karolinska Inst, Dept Oncol Pathol, Solna, Sweden
[10] Karolinska Univ Hosp, Breast Canc Ctr, Canc Theme, Solna, Sweden
[11] Philipps Univ Marburg, Inst Pathol, Marburg, Germany
[12] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Hematol Oncol, Seoul, South Korea
[13] Westmead Hosp, Dept Med Oncol, Sydney, NSW, Australia
[14] Univ Sydney, Sydney, NSW, Australia
[15] Univ Munich LMU, Breast Ctr, Dept Gynecol & Obstet, Munich, Germany
[16] NKO Hokkaido Canc Ctr, Dept Breast Surg, Sapporo, Hokkaido, Japan
[17] Friedrich Alexander Univ Erlangen Nuremberg, Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, Gynecol & Obstet, Erlangen, Germany
[18] Champalimaud Fdn, Breast Unit, Canc Ctr, Lisbon, Portugal
[19] Merck & Co Inc, Biostat, Kenilworth, NJ USA
[20] Merck & Co Inc, Dept Oncol, Kenilworth, NJ USA
[21] Merck & Co Inc, Biostat, N Wales, PA USA
[22] Baylor Univ, Med Ctr, Breast Oncol, Dallas, TX USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA8_PR
引用
收藏
页码：853 / 854
页数：2
相关论文
共 50 条
  • [31] KEYNOTE-355 Asian subset: Pembrolizumab plus chemotherapy vs placebo plus chemotherapy for triple-negative breast cancer
    Takano, Toshimi
    Cortes, Javier
    Cescon, David W.
    Im, Seock-Ah
    Yusof, Mastura Md
    Iwata, Hiroji
    Masuda, Norikazu
    Huang, Chiun-Sheng
    Chung, Chi-Feng
    Tsugawa, Koichiro
    Park, Yeon Hee
    Matsumoto, Koji
    Inoue, Kenichi
    Kwong, Ava
    Loi, Sherene
    Fu, Wei
    Pan, Wilbur
    Karantza, Valia
    Rugo, Hope S.
    Schmid, Peter
    ANNALS OF ONCOLOGY, 2022, 33 : S465 - S465
  • [32] Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866
    Siefker-Radtke, Arlene O.
    Steinberg, Gary D.
    Bedke, Jens
    Nishiyama, Hiroyuki
    Fang, Xiao
    Kataria, Ritesh
    Moreno, Blanca Homet
    Hoimes, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [33] Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation
    Im, S-A.
    Cortes, J.
    Lipatov, O.
    Goncalves, A.
    Lee, K-S.
    Schmid, P.
    Tamura, K.
    Testa, L.
    Witzel, I.
    Ohtani, S.
    Zambelli, S.
    Harbeck, N.
    Andre, F.
    Dent, R.
    Lin, J.
    Karantza, V.
    Mejia, J. A.
    Winer, E. P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1258 - S1258
  • [34] Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522
    Schmid, Peter
    Cortes, Javier
    Dent, Rebecca
    Pusztai, Lajos
    McArthur, Heather
    Kuemmel, Sherko
    Bergh, Jonas
    Denkert, Carsten
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Untch, Michael
    Fasching, Peter A.
    Cardoso, Fatima
    Andersen, Jay
    Patt, Debra
    Danso, Michael
    Ferreira, Marta
    Mouret-Reynier, Marie-Ange
    Im, Seock-Ah
    Ahn, Jin Hee
    Gion, Maria
    Baron-Hay, Sally
    Boileau, Jean-Francois
    Zhu, Yalin
    Pan, Wilbur
    Tryfonidis, Konstantinos
    Karantza, Vassiliki
    O'Shaughnessy, Joyce
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 117 - 118
  • [35] Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro) plus chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial
    Loi, S.
    Schmid, P.
    Aktan, G.
    Karantza, V.
    Salgado, R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
    Cortes, J.
    Lipatov, O.
    Im, S-A.
    Goncalves, A.
    Lee, K. S.
    Schmid, P.
    Tamura, K.
    Testa, L.
    Witzel, I.
    Ohtani, S.
    Zambelli, S.
    Harbeck, N.
    Andre, F.
    Dent, R.
    Zhou, X.
    Karantza, V.
    Mejia, J. A.
    Winer, E. P.
    ANNALS OF ONCOLOGY, 2019, 30 : 859 - +
  • [37] KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
    Gadgeel, S.
    Rodriguez-Abreu, D.
    Felip, E.
    Esteban, E.
    Speranza, G.
    Reck, M.
    Hui, R.
    Boyer, M.
    Garon, E. B.
    Horinouchi, H.
    Cristescu, R.
    Aurora-Garg, D.
    Lunceford, J.
    Kobie, J.
    Ayers, M.
    Piperdi, B.
    Pietanza, M. C.
    Garassino, M. C.
    ANNALS OF ONCOLOGY, 2019, 30 : 64 - 65
  • [38] Pembrolizumab (Pembro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (KEYNOTE-859): Asia subgroup analysis
    Oh, D-Y.
    Bai, Y.
    Ryu, M. H.
    Lee, J.
    Li, J.
    Luo, S.
    Pan, H.
    Qu, Y.
    Lu, J.
    Yang, L.
    Yasui, H.
    Yabusaki, H.
    Yen, C. J.
    Chan, W. W. L.
    Yamaguchi, K.
    Yeh, K-H.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Rha, S. Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1526
  • [39] IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab plus chemo in early triple-negative breast cancer (TNBC)
    Saji, S.
    Mittendorf, E.
    Harbeck, N.
    Zhang, H.
    Barrios, C. H.
    Hegg, R.
    Koehler, A.
    Sohn, J.
    Iwata, H.
    Telli, M. L.
    Ferrario, C.
    Punie, K.
    Llorca, F. Penault
    Patel, S.
    Duc, A. Nguyen
    Hermoso, M. Liste
    Maiya, V.
    Molinero, L.
    Chui, S.
    Jung, K. H.
    ANNALS OF ONCOLOGY, 2020, 31 : S1243 - S1243
  • [40] Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355
    Cescon, David W.
    Schmid, Peter
    Rugo, Hope S.
    Im, Seock-Ah
    Yusof, Mastura Md
    Gallardo, Carlos
    Lipatov, Oleg
    Barrios, Carlos H.
    Perez-Garcia, Jose
    Iwata, Hiroji
    Masuda, Norikazu
    Otero, Marco Torregroza
    Gokmen, Erhan
    Loi, Sherene
    Haiderali, Amin
    Zhou, Xuan
    Guo, Zifang
    Nguyen, Allison Martin
    Cortes, Javier
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (05): : 717 - 727
12345